NCT03638440 - Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. | Biotech Hunter

Enrollment

183

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

March 5, 2020

Study Completion Date

March 5, 2020

Conditions

Opioid Induced Constipation

Interventions

DRUG

Naloxegol

Naloxegol is a PEGylated derivative of the μ-opioid receptor antagonist naloxone

Trial Locations (10)

Aalborg University Hospital, Aalborg

Tampere University Hospital, Tampere

Paul Papin à Angers et site René Gauducheau, Nantes

Lubecker Onkologische, Lübeck

Areteion Hospital, Athens

AORN dei Colli, Napoli

Rijnstate hospital, Arnhem

ICO-Hospitalet, Barcelona

Skane University Hospital, Lund

Royal Surrey County Hospital, Guildford